Evidence map›Paper›PMID 42064067›Full record

ArticleFrontiers in immunology2026

The transmembrane IL-15 isoform expressed on human melanoma cells triggers modulatory effects on tumor progression upon stimulation with the soluble IL-15Rα chain.

Sergio Forcelloni, Julien Giron-Michel, Piero Del Boccio, Maria Concetta Cufaro, Alice Di Sebastiano, Francesca Romana Mariotti, Cecilia Ciancaglini, Salem Chouaib, Mael Padelli, Simone Vespa and 11 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Sergio Forcelloni *Innate Lymphoid Cells Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Julien Giron-Michel *INSERM UMRS 1197, Hôpital Paul Brousse, Villejuif Cedex, France.
Piero Del BoccioProteomics and Metabolomics Core Facility, Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.
Maria Concetta CufaroProteomics and Metabolomics Core Facility, Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.
Alice Di SebastianoProteomics and Metabolomics Core Facility, Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy.
Francesca Romana MariottiTumor Immunology Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Cecilia CiancagliniInnate Lymphoid Cells Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Salem ChouaibInstitut National de la Santé et de la Recherche Médicale Unitè Mixte Recherche (INSERM UMR) 1186, Integrative Tumor Immunology and Cancer Immunotherapy, Gustave Roussy, École Pratique des Hautes Études (EPHE), Faculty De Médecine Univ. Paris-Sud, University Paris-Saclay, Villejuif, France.
Mael PadelliINSERM UMRS 1197, Hôpital Paul Brousse, Villejuif Cedex, France.
Simone VespaDepartment of Pediatrics, Hematology, Oncology, Stem Cell Transplantation and Cell Therapy, University Hospital Würzburg, Würzburg, Germany.
Giang Dang MacDepartment of Pediatrics, Hematology, Oncology, Stem Cell Transplantation and Cell Therapy, University Hospital Würzburg, Würzburg, Germany.
Stefan EbertDepartment of Pediatrics, Hematology, Oncology, Stem Cell Transplantation and Cell Therapy, University Hospital Würzburg, Würzburg, Germany.
Stéphanie BuartInstitut National de la Santé et de la Recherche Médicale Unitè Mixte Recherche (INSERM UMR) 1186, Integrative Tumor Immunology and Cancer Immunotherapy, Gustave Roussy, École Pratique des Hautes Études (EPHE), Faculty De Médecine Univ. Paris-Sud, University Paris-Saclay, Villejuif, France.
Enrico MaggiTumor Immunology Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Lorenzo MorettaTumor Immunology Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Paola VaccaInnate Lymphoid Cells Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Nicola TuminoInnate Lymphoid Cells Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Linda QuatriniInnate Lymphoid Cells Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Ignazio CaruanaDepartment of Pediatrics, Hematology, Oncology, Stem Cell Transplantation and Cell Therapy, University Hospital Würzburg, Würzburg, Germany.
Bruno Azzarone *Tumor Immunology Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Silvia Santopolo *Innate Lymphoid Cells Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interleukin-15 (IL-15) is expressed in various cancers, including melanoma, where it exists in distinct membrane-associated isoforms. Primary melanoma cells predominantly express the non-cleavable transmembrane form (tmbIL-15), while metastatic cells also express a cleavable membrane-bound form (mbIL-15) complexed with IL-15Rα. As tmbIL-15 is capable of reverse signaling upon IL-15Rα engagement, we investigated how this signaling axis modulates melanoma cell behavior across tumor stages. Transcriptomic analysis of melanoma patients revealed that high IL-15 expression correlates with immune activation, inflammation and epithelial-to-mesenchymal transition (EMT), along with coordinated upregulation of IL-15 receptor subunits. Proteomic profiling of melanoma cell lines stimulated with soluble IL-15Rα (sIL-15Rα) uncovered distinct, stage-specific responses. Although several proteins were commonly deregulated across cell lines, most showed opposite regulation in primary versus metastatic models, indicating that tmbIL-15 reverse signaling triggers context-dependent programs influenced by tumor progression. A stringent cross-comparison identified five proteins (PSAP, MARCKS, eEF1A1, DDX39B, and RACK1) as consistently and differentially regulated across tumor stages. Further comparison with published NK cell co-culture and EMT cytokine stimulation datasets revealed a subset of shared effectors, notably PSAP, TPM3 isoform 2 and MARCKS, suggesting that IL-15Rα-induced tmbIL-15 signaling is part of the immune editing phenomenon eliciting pro-tumoral activities complementary to the EMT process. Among these, PSAP emerged as the most robustly and consistently modulated effector, upregulated in primary melanoma cells and downregulated in metastatic ones upon sIL-15Rα stimulation. Its expression correlated positively with CD8+ T cell infiltration and negatively with NK cell infiltration, with distinct transcriptomic programs associated with high PSAP expression in primary versus metastatic settings. Altogether, these findings identify PSAP as a stage-specific mediator of tmbIL-15 reverse signaling in melanoma, integrating immune and EMT-related cues with potential implications for tumor progression and microenvironmental remodeling.

Indexed as

Interleukin-15Interleukin-15 Receptor alpha SubunitMelanomaReceptors, Interleukin-15Skin NeoplasmsCell Line, TumorDisease ProgressionEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansProtein IsoformsProteomicsSignal TransductionIL15 protein, humanIL15RA protein, humanInterleukin-15Interleukin-15 Receptor alpha SubunitProtein IsoformsReceptors, Interleukin-15cytokineIL15IL15Rαnatural killer (NK) cellsskin cancer (melanoma)

Identifiers

PMID42064067
PMCPMC13124470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.